Evidence map›Paper›PMID 38796570›Full record

ReviewMolecular biology reports2024

Recent advances in the therapeutic applications of selenium nanoparticles.

Jeba Ajgar Ansari, Jonaid Ahmad Malik, Sakeel Ahmed, Muntaha Manzoor, Nafees Ahemad, Sirajudheen Anwar

Abstract readReview
In one paragraph

Review in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jeba Ajgar Ansari *Department of Pharmaceutics, Government College of Pharmacy, Dr. Babasaheb Ambedkar Marathwada University, (BAMU, Aurangabad), India.
Jonaid Ahmad Malik *Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, India.
Sakeel AhmedDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Ahmedabad, Gujarat, India.
Muntaha ManzoorDepartment of Clinical Pharmacology, Sher - i - Kashmir Institute of Medical Sciences, Soura, Srinagar, India.
Nafees AhemadSchool of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Petaling Jaya, Selangor, DE, 47500, Malaysia. nafees.ahemad@monash.edu.
Sirajudheen AnwarDepartment of Pharmacology & Toxicology, College of Pharmacy, University of Hail, Hail, Saudi Arabia. si.anwar@uoh.edu.sa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selenium nanoparticles (SeNPs) are an appealing carrier for the targeted delivery. The selenium nanoparticles are gaining global attention because of the potential therapeutic applications in several diseases e.g., rheumatoid arthritis (RA), inflammatory bowel disease (IBD), asthma, liver, and various autoimmune disorders like psoriasis, cancer, diabetes, and a variety of infectious diseases. Despite the fact still there is no recent literature that summarises the therapeutic applications of SeNPs. There are some challenges that need to be addressed like finding targets for SeNPs in various diseases, and the various functionalization techniques utilized to increase SeNP's stability while facilitating wide drug-loaded SeNP distribution to tumor areas and preventing off-target impacts need to focus on understanding more about the therapeutic aspects for better understanding the science behind it. Keeping that in mind we have focused on this gap and try to summarize all recent key targeted therapies for SeNPs in cancer treatment and the numerous functionalization strategies. We have also focused on recent advancements in SeNP functionalization methodologies and mechanisms for biomedical applications, particularly in anticancer, anti-inflammatory, and anti-infection therapeutics. Based on our observation we found that SeNPs could potentially be useful in suppressing viral epidemics, like the ongoing COVID-19 pandemic, in complement to their antibacterial and antiparasitic uses. SeNPs are significant nanoplatforms with numerous desirable properties for clinical translation.

Indexed as

NanoparticlesSeleniumAnimalsAnti-Inflammatory AgentsAntineoplastic AgentsCOVID-19Drug Delivery SystemsHumansNeoplasmsSARS-CoV-2Anti-Inflammatory AgentsAntineoplastic AgentsSeleniumClinical translationNanoparticlesNutrientSeleniumTherapeutic application

Identifiers

PMID38796570
PMCPMC11127871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.